Selective cGAS Inhibition Is Cardioprotective After Myocardial Infarction

Le résumé fourni par la source

Activation of the DNA sensor cGAS has emerged as a potential driver of maladaptive inflammation after myocardial infarction. In this study, the authors provide evidence that a newly developed pharmacologic cGAS inhibitor improves cardiac recovery following myocardial infarction. The compound, which can be administered orally, enhanced post-infarct cardiac function and attenuated adverse ventricular dilation. Using spatial transcriptomics, the authors further demonstrate that cGAS inhibition suppresses type I interferon signaling within the infarct border zone, accompanied by reduced expression of stress-associated cardiac remodeling markers such as Nppa. Together, these findings identify cGAS as a therapeutically targetable regulator of post-infarct inflammation and remodeling, and highlight the novelty of an orally bioavailable inhibitor capable of improving cardiac outcomes after myocardial injury.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.